Pre-made Brontictuzumab benchmark antibody ( Whole mAb, anti-NOTCH1 therapeutic antibody, Anti-AOS5/AOVD1/TAN1/hN1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Brontictuzumab biosimilar, Whole mAb, Anti-NOTCH1 Antibody: Anti-AOS5/AOVD1/TAN1/hN1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.
| Products Name (INN Index) | Pre-Made Brontictuzumab biosimilar, Whole mAb, Anti-NOTCH1 Antibody: Anti-AOS5/AOVD1/TAN1/hN1 therapeutic antibody |
|---|---|
| INN Name | Brontictuzumab |
| Target | NOTCH1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | OncoMed Pharmaceuticals,University of Texas M. D. Anderson Cancer Center |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Adenoid cystic carcinoma,Solid tumours,Haematological malignancies,Colorectal cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | NOTCH1 |
| Package |
